Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of radiolabeled RO7269162 in healthy male volunteers
NL-OMON60517Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivegacetor in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Oct 2024; status: completed.
02
Drugs
nivegacetor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60517.